JP2009521521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521521A5 JP2009521521A5 JP2008548072A JP2008548072A JP2009521521A5 JP 2009521521 A5 JP2009521521 A5 JP 2009521521A5 JP 2008548072 A JP2008548072 A JP 2008548072A JP 2008548072 A JP2008548072 A JP 2008548072A JP 2009521521 A5 JP2009521521 A5 JP 2009521521A5
- Authority
- JP
- Japan
- Prior art keywords
- buffer
- composition
- kit
- solution
- thiol protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 21
- 239000000872 buffer Substances 0.000 claims 17
- 239000000243 solution Substances 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 15
- 101710097834 Thiol protease Proteins 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000012141 concentrate Substances 0.000 claims 7
- 239000000463 material Substances 0.000 claims 7
- 230000003204 osmotic effect Effects 0.000 claims 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 230000002797 proteolythic effect Effects 0.000 claims 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000007987 MES buffer Substances 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 4
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 108090000526 Papain Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 239000008351 acetate buffer Substances 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 238000007865 diluting Methods 0.000 claims 3
- 235000019834 papain Nutrition 0.000 claims 3
- 229940055729 papain Drugs 0.000 claims 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229920002307 Dextran Polymers 0.000 claims 2
- 108010024636 Glutathione Proteins 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000007993 MOPS buffer Substances 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 2
- 239000007983 Tris buffer Substances 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 239000007853 buffer solution Substances 0.000 claims 2
- 239000007979 citrate buffer Substances 0.000 claims 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 claims 2
- 229940099500 cystamine Drugs 0.000 claims 2
- 229960002433 cysteine Drugs 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 2
- 238000001804 debridement Methods 0.000 claims 2
- 229960001484 edetic acid Drugs 0.000 claims 2
- YUPQOCKHBKYZMN-UHFFFAOYSA-N ethylaminomethanetriol Chemical group CCNC(O)(O)O YUPQOCKHBKYZMN-UHFFFAOYSA-N 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 206010040882 skin lesion Diseases 0.000 claims 2
- 231100000444 skin lesion Toxicity 0.000 claims 2
- 239000008362 succinate buffer Substances 0.000 claims 2
- -1 thiol compound Chemical class 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 2
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 claims 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75340005P | 2005-12-27 | 2005-12-27 | |
| US60/753,400 | 2005-12-27 | ||
| PCT/IL2006/001492 WO2007074454A2 (en) | 2005-12-27 | 2006-12-27 | Stable enzymatic preparations and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009521521A JP2009521521A (ja) | 2009-06-04 |
| JP2009521521A5 true JP2009521521A5 (https=) | 2010-02-12 |
| JP5435955B2 JP5435955B2 (ja) | 2014-03-05 |
Family
ID=37943776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008548072A Expired - Fee Related JP5435955B2 (ja) | 2005-12-27 | 2006-12-27 | 安定な酵素製剤及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8197808B2 (https=) |
| EP (1) | EP1965763B1 (https=) |
| JP (1) | JP5435955B2 (https=) |
| DK (1) | DK1965763T3 (https=) |
| ES (1) | ES2763724T3 (https=) |
| WO (1) | WO2007074454A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8197808B2 (en) | 2005-12-27 | 2012-06-12 | Ramot At Tel-Aviv University Ltd. | Stable enzymatic preparations and methods of use thereof |
| ATE554769T1 (de) * | 2006-12-06 | 2012-05-15 | Cornell Res Foundation Inc | Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| CA2727432C (en) | 2008-06-12 | 2016-10-11 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| PL2318035T3 (pl) | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| KR20170005191A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법 |
| CN102300989B (zh) | 2009-01-06 | 2015-12-09 | 柯尔朗恩有限责任公司 | 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法 |
| EP2226382A1 (en) | 2009-03-03 | 2010-09-08 | B.R.A.I.N. Biotechnology Research and Information Network AG | Protease for wound conditioning and skin care |
| US8592451B2 (en) | 2009-03-17 | 2013-11-26 | Cornell University | Reversible nondepolarizing neuromuscular blockade agents and methods for their use |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| US9220700B2 (en) | 2009-08-19 | 2015-12-29 | Cornell University | Cysteine for physiological injection |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| SG187534A1 (en) | 2010-08-29 | 2013-03-28 | Vascode Technologies Ltd | A system and methods for multi-tasking in a clientless mobile phone |
| US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
| CN107854737B (zh) * | 2011-08-31 | 2021-03-26 | 凯希特许有限公司 | 减压治疗与清创系统以及方法 |
| CA2862363C (en) * | 2012-02-02 | 2021-06-08 | Joan M. Fallon | Enzyme compositions and use thereof for wound healing |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| AU2016340017B2 (en) * | 2015-10-14 | 2023-10-05 | Newsouth Innovations Pty Limited | Compositions and methods for the treatment of diseases involving mucin |
| JP6952353B2 (ja) * | 2016-01-31 | 2021-10-20 | メディウーンド リミテッド | 創傷を治療するためのデブリードマン組成物 |
| BR112018071405A2 (pt) * | 2016-04-18 | 2019-02-05 | Mediwound Ltd | métodos de debridamento de ferimentos crônicos |
| AU2018250823A1 (en) | 2017-04-10 | 2019-10-17 | Curemark, Llc | Compositions for treating addiction |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| EP4251141A4 (en) * | 2020-11-25 | 2024-10-02 | Topix Pharmaceuticals, Inc. | SCAR TREATMENT COMPOSITION |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB913203A (en) * | 1958-12-30 | 1962-12-19 | Swift & Co | Enzyme formulations for the production of tenderized meat |
| US3539451A (en) * | 1968-05-31 | 1970-11-10 | Castle & Cooke | Production of reversibly inactivated papain and ficin |
| US4307081A (en) * | 1974-01-08 | 1981-12-22 | Gerold K. V. Klein | Enzyme mixture |
| US4715899A (en) * | 1982-10-21 | 1987-12-29 | Subir Chanda | Liquid cleaner containing inactivated protease for protein soiled contact lenses |
| JPH0449299A (ja) * | 1990-06-14 | 1992-02-18 | Tosoh Corp | 免疫グロブリンフラグメントの精製法 |
| DE4026591B4 (de) | 1990-08-23 | 2005-08-25 | Pleva Gmbh | Vorrichtung zur Bestimmung der Beladung von Luft mit Dämpfen |
| JP2665639B2 (ja) * | 1992-01-09 | 1997-10-22 | テーオー食品株式会社 | 安定化されたチオール蛋白分解酵素を含む焼き肉のタレ |
| US7364565B2 (en) | 2001-07-27 | 2008-04-29 | Ramot At Tel Aviv University Ltd. | Controlled enzymatic removal and retrieval of cells |
| MXPA04004479A (es) * | 2001-11-13 | 2004-08-11 | Procter & Gamble | Composiciones topicas que contienen enzimas estabilizadas con inhibidores. |
| US6692726B1 (en) * | 2003-02-11 | 2004-02-17 | Colgate Palmolive Company | Enzyme containing oral composition having enhanced stability |
| DE602004020910D1 (de) * | 2003-10-10 | 2009-06-10 | Cosmedical Aps | Haarwuchshemmung |
| US8197808B2 (en) | 2005-12-27 | 2012-06-12 | Ramot At Tel-Aviv University Ltd. | Stable enzymatic preparations and methods of use thereof |
-
2006
- 2006-12-27 US US12/087,108 patent/US8197808B2/en not_active Expired - Fee Related
- 2006-12-27 ES ES06821673T patent/ES2763724T3/es active Active
- 2006-12-27 JP JP2008548072A patent/JP5435955B2/ja not_active Expired - Fee Related
- 2006-12-27 EP EP06821673.8A patent/EP1965763B1/en not_active Not-in-force
- 2006-12-27 DK DK06821673.8T patent/DK1965763T3/da active
- 2006-12-27 WO PCT/IL2006/001492 patent/WO2007074454A2/en not_active Ceased
-
2012
- 2012-01-16 US US13/350,846 patent/US8337837B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521521A5 (https=) | ||
| Moore et al. | Mechanisms of gastrointestinal ischemia‐reperfusion injury and potential therapeutic interventions: a review and its implications in the horse | |
| US7713929B2 (en) | Rapid acting and long acting insulin combination formulations | |
| Pratt et al. | Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. | |
| Perazella et al. | Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy | |
| Sasaki et al. | Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes | |
| US7718609B2 (en) | Rapid acting and long acting insulin combination formulations | |
| ES2709103T3 (es) | Métodos para conservar órganos y tejidos | |
| Lieberman et al. | Inhibitors and activators of leukocytic proteases in purulent sputum: Digestion of human lung and inhibition by alpha1-antitrypsin | |
| Napolitano et al. | Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure | |
| CA2275890A1 (en) | Stable liquid interferon formulations | |
| JP2010529018A5 (ja) | 医薬組成物、および医薬錠剤 | |
| TWI751379B (zh) | 用於遞送胜肽之藥物組合物 | |
| ATE506071T1 (de) | Formulierung für proteinarzneimittel ohne zusatz von humanem serumalbumin (hsa) | |
| JP2005529847A5 (https=) | ||
| Dasta et al. | Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug | |
| NZ593190A (en) | Factor viii formulations | |
| JP2025163108A5 (https=) | ||
| Orce et al. | Inhibition of short-circuit current in toad urinary bladder by inhibitors of glandular kallikrein | |
| RU2011122629A (ru) | Водная композиция, содержащая фолликулостимулирующий гормон | |
| ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
| JP2006501225A5 (https=) | ||
| JP2008512527A5 (https=) | ||
| JP7158063B2 (ja) | グルカゴン保護剤及びその応用 | |
| Mabuchi et al. | Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum |